The effects of isoliquiritigenin on endometriosis in vivo and in vitro study

Yi-Wen Hsu, Hsin-Yuan Chen, Y-H. Chen, Yi-Fen Chiang, Li-Chun Chang, Po‐Han Lin, Po-Han Lin, Shih-Min Hsia, Shih‐Min Hsia
Phytomedicine : international journal of phytotherapy and phytopharmacology · 2020 · vol. 77 , pp. 153214 · doi:10.1016/j.phymed.2020.153214 · PMID:32736296 · W3029341037
article OA: closed CC0 ⤵ 19 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Isoliquiritigenin reduced endometriotic lesion size and suppressed proliferation and invasion of endometrial cells in vitro.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Chalcones Endometriosis Endometriosis Animals Antigens, CD Antigens, CD Cadherins Cadherins Cell Line Cell Movement Cell Movement Cell Proliferation Cell Proliferation Cell Survival Cell Survival Chalcones Disease Models, Animal Endometriosis Endometriosis Epithelial-Mesenchymal Transition

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (19)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:47.975235+00:00
License: CC0 · commercial use OK